SCHEMBL20118869

SCHEMBL20118869

CCCCN(CC)CCCC(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G1B P04054 1/20 0.47
PLA2G2A P14555 1/20 0.47
KCNH2 Q12809 10/20 0.38
KDM5A P29375 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
SIGMAR1 Q99720 1/20 0.35
CHRM2 P08172 2/20 0.35
SLC6A4 P31645 2/20 0.35
DRD3 P35462 2/20 0.35
CACNA1F O60840 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
CHRM3 P20309 1/20 0.35
HTR2A P28223 1/20 0.35
CACNA1D Q01668 1/20 0.35
CACNA1S Q13698 1/20 0.35
CACNA1C Q13936 1/20 0.35
LMNA P02545 1/20 0.35
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5948799 0.93 PLA2G1B (0.41) PLA2G1BPLA2G2AKCNH2KDM4CSIGMAR1
SCHEMBL21155222 0.91 PLA2G1B (0.42) PLA2G1BPLA2G2AKCNH2SIGMAR1CHRM2
SCHEMBL17277117 0.90 PLA2G1B (0.40) PLA2G1BPLA2G2AKDM5AKDM4CLMNA
SCHEMBL441038 0.87 SIGMAR1 (0.43) PLA2G1BPLA2G2AKCNH2SIGMAR1CHRM2
SCHEMBL21238513 0.86 PLA2G1B (0.38) PLA2G1BPLA2G2AKDM5ALMNACA12
SCHEMBL19840410 0.86 PLA2G1B (0.42) PLA2G1BPLA2G2AKCNH2KDM5AKDM4C
SCHEMBL5948987 0.85 SIGMAR1 (0.47) PLA2G1BPLA2G2AKCNH2KDM5AKDM4C
SCHEMBL23192226 0.84 PLA2G1B (0.50) PLA2G1BPLA2G2AKCNH2KDM5AKDM4C
SCHEMBL10893528 0.83 PLA2G1B (0.48) PLA2G1BPLA2G2AKCNH2KDM4CSIGMAR1
SCHEMBL13309417 0.83 PLA2G1B (0.43) PLA2G1BPLA2G2AKCNH2KDM5AKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827641-B2 Toll-like receptor antagonist compounds and methods of use DYNAVAX TECHNOLOGIES CORPORATION (US) 2023-11-28 US disclosed
US-11230557-B2 mTORC modulators and uses thereof AEOVIAN PHARMACEUTICALS, INC. (US) 2022-01-25 US disclosed
US-20210008041-A1 MTORC MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS, INC. 2021-01-14 US disclosed
WO-2019036384-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2019-02-21 WO disclosed
EP-3315531-A1 8-ARM POLYETHYLENE GLYCOL DERIVATIVE, MANUFACTURING METHOD AND MODIFIED BIO-RELATED SUBSTANCE THEREBY Xiamen Sinopeg Biotech Co., Ltd. (CN) 2018-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210008041-A1 MTORC MODULATORS AND USES THEREOF MTOR, RICTOR, RPTOR PLA2G1B 3633/4885PLA2G2A 3066/4885KCNH2 4854/4885
US-11827641-B2 Toll-like receptor antagonist compounds and methods of use TLR7, TLR9, TLR1 PLA2G1B 2023/4885PLA2G2A 1552/4885KCNH2 2524/4885
US-11230557-B2 mTORC modulators and uses thereof MTOR, RICTOR, RPTOR PLA2G1B 3633/4885PLA2G2A 3066/4885KCNH2 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.